Lowest Price Guaranteed From USD 2,499
Published
January 2017
Pages
654
View Count
6333
Example Insights
An updated edition is available at the following link
Report Description
The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments of the pharmaceutical industry. Harnessing immune system components for developing therapeutic solutions has demonstrated significant clinical benefit for various diseases areas, specifically against a number of oncological indications. Immunotherapeutics have gradually gained a strong foothold in the pharmaceutical industry. Post the early success of immune checkpoint inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.
Adoptive immunotherapy is an emerging concept that involves the passive transfer of immune cells, which may or may not be modified / genetically altered to express a desired set of traits and / or features.Characterized by key features such as target specificity, adaptability and the capability to retain immunologic memory, T-cells have been effectively used as therapeutic tools to mediate an artificial immune response. More specifically, T-cell immunotherapies are classified into three major segments, namely chimeric antigen receptor (CAR) T-cell, T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) based therapies. Academicians across the globe have significantly contributed to this field by convening the initial research on potential product candidates; this has served as the intellectual framework for establishment of several start-ups and evolution of the product portfolios of established players in the industry.
The overall market is expected to witness a significant growth in opportunities for a variety of stakeholders in the coming decade. It is important to highlight that various technology providers, aiming to develop and / or support the development of T-cell immunotherapy products with improved efficacy and safety, have designed and introduced advanced platforms for engineering of T-cells. Innovation in this domain, backed by lucrative rounds of venture capital (VC) funding, has led to the discovery of several novel molecular targets and strengthened the research pipelines of companies focused in this space. The capability to target diverse therapeutic areas is amongst the most prominent growth drivers of this market.
Scope of the Report
The “T-Cell Immunotherapy Market, 2017-2030 (2nd edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders. The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies.
The role of academic players / research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis / University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma / National Cancer Institute), and LN-144 (Lion Biotechnologies / National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies.
Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population.
One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following areas:
With most products still in the early stages of clinical development, we have provided informed estimates of the potential future sales of different CAR-T, TCR and TIL therapies. The research, analysis and insights presented in this report are backed by a deep understanding of the key drivers behind the predicted growth. We have provided three market forecast scenarios to add robustness to our model. More specifically, the conservative, base and optimistic forecast scenarios represent three different tracks of the industry’s evolution, taking into account the ambiguities associated with the development and approval of pharmaceutical products. All actual figures have been sourced from publicly available information. All figures mentioned in this report are in USD, unless otherwise specified.
A detailed press release of this report can be foud here.
Contents
Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.
Chapter 3 provides a general introduction to T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of oncological indications, the advent of cancer immunotherapy and the factors supporting the growing popularity of T-cell based therapies.
Chapter 4 provides a comprehensive overview of the current landscape of the T-cell immunotherapy market. It features information on various types of therapies that are currently in different stages of development (clinical and preclinical / discovery). It includes a detailed analysis of the T-cell immunotherapy pipeline, specifically, providing information on the most commonly targeted disease indications, current phases of development of individual therapies, specific molecular targets, type of developer(s) and the key companies involved in the development of different types of T-cell therapies, namely CAR-T, TCR and TIL.
Chapter 5 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.
Chapter 6 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.
Chapter 7 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.
Chapter 8 features an elaborate discussion on the future opportunity presented by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are in the advanced stages of development (phase I/II, phase II and phase II/III), taking into consideration the target patient population, existing competition, likely adoption rates and the likely price of T-cell therapies.
Chapter 9 provides an analysis of the various T-cell therapies that are being developed for the treatment of commonly targeted indications, including hematological cancers and solid tumors. It is worth mentioning that the aforementioned types of oncological indications have been the prime focus of companies developing T-cell immunotherapies. The section also highlights key epidemiological facts and the currently available treatment solutions for each indication.
Chapter 10 focuses on emerging technological platforms that mediate/assist the growth of the T-cell market. It includes detailed discussions on various novel and innovative technologies, along with brief information about key technology providers.
Chapter 11 provides an overview of the emerging trends related to T-cell immunotherapy on social media. It includes data representing the popularity of T-cell products on Twitter over the last five years.
Chapter 12 presents a detailed analysis on the partnerships and agreements established between various players concerning T-cell immunotherapies in the past few years. The section also highlights the financial details of the agreements (wherever available). The partnership activity in this domain has been analyzed on the basis of the year of establishment of the company, the type of partnership model employed, the companies involved, therapy type and prominent product candidates involved.
Chapter 13 provides details on the various investments and grants awarded to players focused on the development of T-cell immunotherapies. The analysis highlights the growing interest of the VC community and other strategic investors in this domain.
Chapter 14 offers details of other novel T-cell based technologies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. We have provided a brief overview of these upcoming therapies, along with details of their mechanisms of action and the process followed for dose administration.
Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities.For these players, we have included details, such as the scale of operation, compliance to cGMP standards, location of various manufacturing facilities and the products being manufactured.
Chapter 16 highlights our view point on the various factors that must be considered while pricing the cell based therapies. It features discussions on different models / approaches that a pharmaceutical company can follow to decide the price at which their T-cell based immunotherapy product is likely to be marketed.
Chapter 17 includes detailed company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes information such as financial performance, geographical presence, T-cell immunotherapy pipeline, collaborations and recent developments. Additionally, we have also provided details of the strategic / venture capital investments made in these companies.
Chapter 18 is a collection of transcripts of interviews conducted during the course of this study. In this chapter, we have presented the details of our conversations with Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Lion Biotechnologies), AinoKalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma) and Miguel Forte (Chief Operating Officer, TxCell).
Chapter 19 summarizes the entire report. Here, we have provided a list of key takeaways and our independent opinion on the current state and future opportunity in this field.
Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 21 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining a Strong Foothold
3.4. Immuno-Oncology: Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Cell Based Therapies
3.6. T-Cell Immunotherapy: Historical Evolution
3.7. T-Cell Immunotherapy: Key Considerations
3.8. Strategies Employed for Redirection of T-Cells
3.9. T-Cell Transduction / Transfection Methods
3.9.1. Retroviral Vectors
3.9.2. Lentiviral Vectors
3.9.3. Non-viral Transfection Methods
3.9.3.1. Sleeping Beauty Transposon
3.10. T-Cell Immunotherapy: Targeted Therapeutic Areas
3.11. T-Cell Immunotherapy: Key Challenges
4. Market Landscape
4.1. Chapter Overview
4.2. T-Cell Immunotherapy: An Evolving Landscape
4.3. T-Cell Immunotherapy: A Promising Pipeline
4.3.1. T-Cell Immunotherapy: CAR-T Cells
4.3.1.1. Clinical Pipeline
4.3.1.2. Preclinical / Discovery Pipeline
4.3.2. T-Cell Immunotherapy: TCR Cells
4.3.2.1. Clinical Pipeline
4.3.2.2. Preclinical / Discovery Pipeline
4.3.3. T-Cell Immunotherapy: TIL Cells
4.3.3.1. Clinical Pipeline
4.3.3.2. Preclinical / Discovery Pipeline
4.4. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Product
4.5. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Developer
4.6. T-Cell Immunotherapy: Distribution of Candidate Therapies by Phase of Development
4.7. T-Cell Immunotherapy: Target Oncological Indications
4.7.1. CAR-T Cell Immunotherapy: Popular Target Indications
4.7.2. TCR Cell Immunotherapy: Popular Target Indications
4.7.3. TIL Cell Immunotherapy: Popular Target Indications
4.8. T-Cell Immunotherapy: Key Industry Players
4.9. T-Cell Immunotherapy: Key Non-Industry Players
4.10. T-Cell Immunotherapy: Most Popular Targets for CAR-T and TCR Therapies
5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
5.1. Introduction
5.2. History of Development
5.3. Key Opinion Leaders
5.4. Anatomical Layout of Chimeric Antigen Receptor
5.5. Development of Chimeric Antigen Receptors
5.6. Development of CAR-T Cells
5.7. Universal CAR-Ts
5.8. Route of Administration
5.9. Toxicity Issues
5.9.1. Cytokine Release Syndrome (CRS)
5.9.2. On-Target Off-Tumor Toxicity
5.9.3. Encephalopathy and B-Cell Aplasia
5.10. Management of Toxicity Issues
5.10.1. Target Selection
5.10.2. Cell Persistence
5.10.3. Receptor Expression
5.11. CD19: An Attractive Target
5.12. Other Targets
5.13. Challenges Associated with CAR-T Therapy
5.13.1. Competitive Risks
5.13.2. Clinical Risks
5.13.3. Regulatory Risks
5.13.4. Commercial Risks
5.14. CTL019 (Novartis)
5.14.1. Introduction
5.14.2. History of Development
5.14.3. Development Status
5.14.4. Key Clinical Trial Results
5.14.4.1. Acute Lymphoblastic Leukemia
5.14.4.2. Non-Hodgkin’s Lymphoma
5.14.4.3. Chronic Lymphocytic Leukemia
5.14.4.4. Multiple Myeloma
5.14.5. Dosage Regimen, Treatment Cost and Manufacturing
5.15. JCAR (Juno Therapeutics)
5.15.1. Introduction
5.15.2. CAR-T Design
5.15.3. Development Status
5.15.4. Key Clinical Trial Results
5.15.4.1. JCAR014
5.15.4.2. JCAR015
5.15.4.3. JCAR017
5.15.4.4. JCAR018
5.15.5. Dosage Regimen and Manufacturing
5.16. KTE-C19 (Kite Pharma)
5.16.1. Introduction
5.16.2. Development Status
5.16.3. Key Clinical Trial Results
5.16.3.1. Non-Hodgkin’s Lymphoma
5.16.3.2. Acute Lymphoblastic Leukemia
5.16.4. Dosage Regimen and Manufacturing
5.16.5. Next Generation eACT CAR Candidates
5.17. CAR-T Series (Cellular Biomedicine Group)
5.17.1. Introduction
5.17.2. History of Development
5.17.3. Development Status
5.17.4. Key Clinical Trial Results
5.17.4.1. CBM-EGFR.1
5.17.4.2. CBM-C19.1
5.17.4.3. CBM-C20.1
5.17.4.4. CBM-C30.1
5.17.5. Dosage Regimen, Manufacturing and Patent Portfolio
5.18. CD19 CAR (Takara Bio)
5.18.1. Introduction
5.18.2. Development Status
5.18.3. Key Clinical Trial Results
5.18.4. Dosage Regimen and Manufacturing
6. T-Cell Receptor (TCR) Based Therapies
6.1. Introduction
6.2. Structure of the T-Cell Receptor
6.3. Difference between CAR and TCR
6.4. History of Development
6.5. Key Opinion Leaders
6.6. Mechanism of Action
6.7. Safety Issues
6.7.1. Insertional Mutagenesis
6.7.2. On-Target Off-Tumor Toxicity and Cross-Reactivity
6.7.3. TCR Mismatch Pairing
6.8. Prerequisites of Antigen-Specific T-Cell Receptors
6.9. Identifying Strategies that Enhance Antitumor Efficacy
6.9.1. Affinity Enhanced TCRs
6.9.2. Soluble TCR Based Biologics
6.10. SPEAR T-Cells (Adaptimmune)
6.10.1. Introduction
6.10.1.1. NY-ESO SPEAR T-Cell
6.10.1.2. Mage-A10 T-Cell Therapy
6.10.1.3. AFP T-Cell therapy
6.10.2. History of Development
6.10.3. SPEAR T-cells Technology Platform
6.10.4. Development Status
6.10.5. Key Clinical Trial Results
6.10.5.1. Multiple Myeloma
6.10.5.2. Synovial Sarcoma
6.10.5.3. Ovarian Cancer
6.10.5.4. Multiple Myeloma, Synovial Sarcoma and Ovarian Cancer: Combined Results
6.10.6. Dosage Regimen and Manufacturing Information
6.11. ALT-801 (AltorBioScience)
6.11.1. Introduction
6.11.2. History of Development
6.11.3. Development Status
6.11.4. Key Clinical Trial Results
6.11.4.1. Urothelial Carcinoma
6.11.4.2. Bladder Cancer
6.11.5. Dosage Regimen and Patent Portfolio
6.12. IMCgp100 (Immunocore)
6.12.1. Introduction
6.12.2. Development Status
6.12.3. Key Clinical Trial Results
6.12.4. Dosage Regimen
6.13. JTCR016 (Juno Therapeutics)
6.13.1. Introduction
6.13.2. Development Status
6.13.3. Key Clinical Trial Results
6.13.4. Dosage Regimen
6.14. WT1 TCR Gene Therapy (Cell and Gene Therapy Catapult)
6.14.1. Introduction
6.14.2. History of Development
6.14.3. Development Status
6.14.4. Key Clinical Trial Results
6.14.5. Dosage Regimen and Manufacturing
7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies
7.1. Introduction
7.2. History of Development
7.3. Key Opinion Leaders
7.4. Research Strategies to Enhance Efficacy
7.5. A Prognostic Tool
7.6. Manufacturing Process
7.7. LN-144 (Lion Biotechnologies)
7.7.1. Introduction
7.7.2. Development Status
7.7.3. Key Clinical Trial Results
7.7.4. Dosage Regimen and Manufacturing
7.7.5. Patent Portfolio
7.7.6. Next-Generation TILs
7.8. TIL (Nantes University Hospital)
7.8.1. Introduction
7.8.2. Development Status
7.8.3. Key Experimental Results
7.8.4. Dosage Regimen and Manufacturing
7.9. TIL (Netherlands Cancer Institute)
7.9.1. Introduction
7.9.2. Development Status
7.9.3. Key Clinical Trial Results
7.9.4. Dosage Regimen and Manufacturing
8. Market Opportunity
8.1. Chapter Overview
8.2. Scope and Limitations
8.3. Forecast Methodology
8.4. Overall T-Cell Immunotherapy Market(Till 2030)
8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Market
8.5.1. CTL019 (Novartis)
8.5.1.1. Target Population
8.5.1.2. Sales Forecast(Till 2030)
8.5.2. KTE-C19 (Kite Pharma)
8.5.2.1. Target Population
8.5.2.2. Sales Forecast (Till 2030)
8.5.3. JCAR015 (Juno Therapeutics)
8.5.3.1. Target Population
8.5.3.1.1. Sales Forecast(Till 2030)
8.5.4. CBM-CD30 CAR-T (Cellular Biomedicine Group)
8.5.4.1. Target Population
8.5.4.2. Sales Forecast (Till 2030)
8.5.5. CBM-CD20 CAR-T (Cellular Biomedicine Group)
8.5.5.1. Target Population
8.5.5.2. Sales Forecast(Till 2030)
8.5.6. CBM-EGFR.1 CAR-T (Cellular Biomedicine Group)
8.5.6.1. Target Population
8.5.6.2. Sales Forecast (Till 2030)
8.5.7. CD 19 CAR-T (Sinobioway Cell Therapy)
8.5.7.1. Target Population
8.5.7.2. Sales Forecast (Till 2030)
8.5.8. CD 19 CAR-T (Takara Bio)
8.5.8.1. Target Population
8.5.8.2. Sales Forecast (Till 2030)
8.5.9. GPC3 CAR-T (Shanghai Genechem)
8.5.9.1. Target Population
8.5.9.2. Sales Forecast (Till 2030)
8.5.10. JCAR017 (Juno Therapeutics)
8.5.10.1. Target Population
8.5.10.2. Sales Forecast (Till 2030)
8.6. Overall TCR Market (Till 2030)
8.6.1. IMCgp100 (Immunocore)
8.6.1.1. Target Population
8.6.1.2. Sales Forecast(Till 2030)
8.6.2. HPV-16E6-TCR (Kite Pharma)
8.6.2.1. Target Population
8.6.2.2. Sales Forecast (Till 2030)
8.6.3. NY-ESO-1 TCR (Adaptimmune)
8.6.3.1. Target Population
8.6.3.2. Sales Forecast(Till 2030)
8.6.4. HBV antigen specific TCR redirected T-Cell (Lion TCR)
8.6.4.1. Target Population
8.6.4.2. Sales Forecast(Till 2030)
8.6.5. ALT-801 (AltorBioScience)
8.6.5.1. Target Population
8.6.5.2. Sales Forecast(Till 2030)
8.6.6. JTCR016 (Juno Therapeutics)
8.6.6.1. Target Population
8.6.6.2. Sales Forecast (Till 2030)
8.6.7. KITE-718 (MAGE A3/A6) (Kite Pharma)
8.6.7.1. Target Population
8.6.7.2. Sales Forecast (Till 2030)
8.6.8. MAGE A3 (Kite Pharma)
8.6.8.1. Target Population
8.6.8.2. Sales Forecast (Till 2030)
8.6.9. WT-1 TCR (Cell Therapy Catapult)
8.6.9.1. Target Population
8.6.9.2. Sales Forecast(Till 2030)
8.6.10. MAGE A-10 TCR (Adaptimmune)
8.6.10.1. Target Population
8.6.10.2. Sales Forecast(Till 2030)
8.7. Overall TIL Therapy Market (Till 2030)
8.7.1. LN-144 (Lion Biotechnologies)
8.7.1.1. Target Population
8.7.1.2. Sales Forecast (Till 2030)
8.7.2. TIL Therapy (Nantes University)
8.7.2.1. Target Population
8.7.2.2. Sales Forecast (Till 2030)
8.7.3. TIL Therapy (Netherlands Cancer Institute)
8.7.3.1. Target Population
8.7.3.2. Sales Forecast (Till 2030)
9. Key Therapeutic Areas for T-Cell Therapies
9.1. Chapter Overview
9.2. Introduction
9.3. Hematological Malignancies
9.3.1. Leukemia and Lymphoma
9.3.1.1. Leukemia: Introduction and Epidemiology
9.3.1.1.1. Acute Myeloid Leukemia (AML)
9.3.1.1.2. Chronic Myeloid Leukemia (CML)
9.3.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.3.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.3.1.2. Lymphoma: Introduction and Epidemiology
9.3.1.3. Current Treatment Landscape
9.3.1.3.1. Targeted Therapies
9.3.1.4. T-Cell Immunotherapy and Research Landscape
9.3.1.4.1. CAR-Ts and Leukemia / Lymphoma
9.3.1.4.2. TCRs and Leukemia / Lymphoma
9.3.2. Multiple Myeloma
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. T-Cell Immunotherapy and Research Landscape
9.4. Solid Tumors
9.4.1. Metastatic Melanoma
9.4.1.1. Introduction and Epidemiology
9.4.1.2. Current Treatment Landscape
9.4.1.3. T-Cell Immunotherapy and Research Landscape
9.4.1.3.1. TILs and Metastatic Melanoma
9.4.1.3.1.1. TIL Research at the MD Anderson Cancer Center, US
9.4.1.3.1.2. TIL Research at the Sheba Medical Centre, Israel
9.4.1.3.2. TCRs and Metastatic Melanoma
9.4.1.3.3. CAR-Ts and Metastatic Melanoma
9.4.2. Lung Cancer
9.4.2.1. Introduction and Epidemiology
9.4.2.2. Current Treatment Landscape
9.4.2.3. T-Cell Immunotherapy and Research Landscape
9.4.3. Bladder Cancer
9.4.3.1. Introduction and Epidemiology
9.4.3.2. Current Treatment Landscape
9.4.3.3. T-Cell Immunotherapy and Research Landscape
9.4.4. Kidney Cancer
9.4.4.1. Introduction and Epidemiology
9.4.4.2. Current Treatment Landscape
9.4.4.3. T-Cell Immunotherapy and Research Landscape
9.4.5. Ovarian Cancer
9.4.5.1. Introduction and Epidemiology
9.4.5.2. Current Treatment Landscape
9.4.5.3. T-Cell Immunotherapy and Research Landscape
9.4.5.3.1. CAR-Ts and Ovarian Cancer
9.4.6. Breast Cancer
9.4.6.1. Introduction and Epidemiology
9.4.6.2. Current Treatment Landscape
9.4.6.3. T-Cell Immunotherapy and Research Landscape
9.4.6.3.1. CAR-Ts and Breast Cancer
9.4.6.3.2. TILs and Breast Cancer
10. Emerging Technologies
10.1. Chapter Overview
10.2. Introduction
10.3. Genome Editing Technologies: Introduction
10.4. Genome Editing Technologies: Applications
10.4.1. Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Therapies
10.4.1.1. CRISPR/Cas9 System
10.4.1.1.1. Key Components and Function
10.4.1.1.2. Mechanism of Action
10.4.1.1.3. Targeting Efficiency and Challenges
10.4.1.1.4. Next-GEN CRISPR Technology
10.4.1.1.5. Technology Providers
10.4.1.1.5.1. Editas Medicine
10.4.1.1.5.2. Intellia Therapeutics
10.4.1.1.5.3. CRISPR Therapeutics
10.4.1.2. TALENs
10.4.1.2.1. Structural Features
10.4.1.2.2. Mechanism of Action
10.4.1.2.3. Advantages and Challenges
10.4.1.2.4. Technology Providers
10.4.1.2.4.1. Cellectis
10.4.1.2.4.2. Editas Medicine
10.4.1.3. megaTAL
10.4.1.3.1. Technology Providers
10.4.1.3.1.1. bluebird bio
10.4.1.4. Zinc Finger Nuclease
10.4.1.4.1. Technology Providers
10.4.1.4.1.1. Sangamo Biosciences
10.5. Designing T-Cell Therapies with Improved Characteristics
10.5.1. Technology for Targeting Multiple Cancers
10.5.1.1. Antibody Coupled T-Cell Receptor, Unum Therapeutics
10.5.1.2. NKR-T Platform, Celyad
10.5.2. Technology For Improved Safety
10.5.2.1. Armored CAR, Juno Therapeutics
10.5.2.2. RheoSwitch Therapeutic System, Intrexon
10.5.2.3. Inducible Caspase 9 Safety Switch, BellicumPharmaceuticals
10.5.2.3.1. CaspaCIDe Technology
10.5.2.3.2. CIDeCAR Technology
10.5.2.3.3. GoCAR-T Technology
10.5.2.4. On-Off Switch, Multiple Companies
10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
10.5.2.4.2. On-Off Switch, Theravectys
10.5.2.5. Allogeneic Technology
10.5.2.5.1. CIK CAR-T Cells, Formula Pharmaceuticals
10.5.2.5.2. Allogeneic Platform, Celyad
10.5.2.5.3. Allogeneic Platform, Cellectis
11. Social Media: Emerging Trends
11.1. Chapter Overview
11.2. Trends on Twitter
11.2.1. Yearly Trends on Twitter
11.2.2. Popular Keywords on Twitter
11.2.3. Most Popular Drugson Twitter
12. Partnerships and Collaborations
12.1. Chapter Overview
12.2. Partnership Models
12.3. Recent Collaborations
12.3.1. Distribution of Partnerships by Year
12.3.2. Distribution of Partnerships by Type of Model
12.3.3. Leading Industry Collaborators
12.3.4. Leading Non-Industry Collaborators
12.3.5. Distribution of Partnerships by Type of Therapy
12.3.6. Distribution of Partnerships by Product Therapy
13. Venture Capital Support
13.1. Chapter Overview
13.2. T-Cell Immunotherapy: List of Funding Instances
13.2.1. T-Cell Immunotherapy: Funding Instances, Cumulative Number of Funding Instances by Year, pre-2009-2016
13.2.2. T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016
13.2.3. T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
13.2.4. T-Cell Immunotherapy: Funding Instances, Distribution of Amount Invested by Type of Funding
14. Other T-Cell Immunotherapies
14.1. Chapter Overview
14.2. Other T-Cell Immunotherapies
14.2.1. Treg Cell Therapy
14.2.1.1. Caladrius Biosciences
14.2.1.2. TxCell
14.2.1.3. TRACT Therapeutics
14.2.1.4. Other Companies
14.2.2. T-Cell Based Vaccines
14.2.2.1. Immunovative Therapies
14.2.2.2. Opexa Therapeutics
14.2.2.3. TVAX
14.2.3. Virus-Driven T-Cell Therapies
14.2.3.1. Atara Biotherapeutics
14.2.3.2. Cell Medica
14.2.3.3. Tessa Therapeutics
14.2.4. Fucosylation Technology Platform
14.2.4.1. Targazyme
14.2.5. PD-1 Knockout Engineered T-Cells
14.2.5.1. Chengdu MedGenCell
14.2.6. TAC-T Cells
14.2.6.1. Triumvira
14.2.7. Vγ9δ2 T cell T-Cell immunotherapy
14.2.7.1. GammaCell Biotechnologies
15. Case Study: Cell Therapy Manufacturing
15.1. Chapter Overview
15.2. Introduction
15.3. Key Challenges
15.4. Current Trends
15.4.1. Companies with In-house Capabilities
15.4.2. Contract Manufacturers
15.5. Key Considerations for a Manufacturing Site
15.6. Regulatory Landscape
16. T-Cell Immunotherapy: Cost Price Analysis
16.1. Chapter Overview
16.2. Cell / Gene Therapies: Factors Contributing Towards Higher Price Tags
16.3. T-Cell Immunotherapy: Pricing Models
16.3.1. Pricing Model: Based On Associated Costs
16.3.2. Pricing Model: Based On Competition
16.3.3. Pricing Model: Based on Expert Opinions
17. Company Profiles
17.1. Chapter Overview
17.2. Adaptimmune
17.2.1. Company Overview
17.2.2. Financial Information
17.2.3. Product Portfolio
17.2.4. Manufacturing Capabilities
17.2.5. Collaborations
17.2.5.1. Immunocore
17.2.5.2. Progenitor Cell Therapy
17.2.5.3. Thermo Fisher Scientific
17.2.5.4. GlaxoSmithKline
17.2.5.5. Universal Cells
17.2.5.6. MD Anderson Cancer Center
17.2.5.7. Merck
17.2.5.8. Bellicum Pharmaceuticals
17.2.6. Future Outlook
17.3. AltorBioScience
17.3.1. Company Overview
17.3.2. Financial Performance
17.3.3. Product Portfolio
17.3.4. Patent Portfolio
17.3.5. Collaborations
17.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
17.3.5.2. National Cancer Institute (NCI)
17.3.5.3. NantKwest
17.3.6. Future Outlook
17.4. bluebird Bio
17.4.1. Company Overview
17.4.2. Financial Performance
17.4.3. Product Portfolio
17.4.4. Collaborations
17.4.4.1. Celgene Corporation
17.4.4.2. Baylor College of Medicine
17.4.4.3. Pregenen
17.4.4.4. Five Prime Therapeutics
17.4.4.5. Kite Pharma
17.4.4.6. ViroMed
17.4.5. Future Outlook
17.5. Cellectis
17.5.1. Company Overview
17.5.2. Financial Information
17.5.3. Product Portfolio
17.5.4. Collaborations
17.5.4.1. Servier
17.5.4.2. CELLforCURE
17.5.4.3. Pfizer
17.5.4.4. Oncodesign
17.5.4.5. Ohio University
17.5.4.6. Weill Cornell Medical College
17.5.4.7. The University of Texas MD Anderson Cancer Center
17.5.4.8. Takara Biosciences
17.5.4.9. MabQuest
17.5.5. Future Outlook
17.6. Cellular Biomedicine Group
17.6.1. Company Overview
17.6.2. Financial Information
17.6.3. Product Portfolio
17.6.4. Manufacturing Capabilities
17.6.5. Collaborations
17.6.5.1. Agreen Biotech
17.6.5.2 Chinese PLA General Hospital
17.6.6. Future Outlook
17.7. Immunocore
17.7.1. Company Overview
17.7.2. Financial Information
17.7.3. Product Portfolio
17.7.4. Collaborations
17.7.4.1. Cardiff University
17.7.4.2. Genentech
17.7.4.3. GlaxoSmithKline
17.7.4.4. Medimmune
17.7.4.5. Eli Lilly
17.7.4.6. CMC Biologics
17.7.5. Future Outlook
17.8. Juno Therapeutics
17.8.1. Company Overview
17.8.2. Financial Information
17.8.3. Product Portfolio
17.8.4. Litigations
17.8.5. Manufacturing Capabilities
17.8.6. Collaborations
17.8.6.1. Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Seattle Children’s Research Institute
17.8.6.2. Opus Bio
17.8.6.3. MedImmune/AstraZeneca
17.8.6.4. Stage Cell Therapeutics
17.8.6.5. Editas Medicine
17.8.6.6. Fate Therapeutics
17.8.6.7. X-Body
17.8.6.8. Celgene
17.8.6.9. AbVitro
17.8.6.10. Wuxi AppTec
17.8.6.11. RedoxTherapies
17.8.6.12. Eureka Therapeutics, Memorial Sloan Kettering Cancer Center
17.8.7. Future Outlook
17.9. Kite Pharma
17.9.1. Company Overview
17.9.2. Financial Information
17.9.3. Product Portfolio
17.9.4. Manufacturing Capabilities
17.9.5. Collaborations
17.9.5.1. National Cancer Institute / National Institutes of Health
17.9.5.2. Cabaret Biotech
17.9.5.3. NeoStem
17.9.5.4. Amgen
17.9.5.5. Tel Aviv Sourasky Medical Center
17.9.5.6. T-Cell Factory (TCF)
17.9.5.7. bluebird bio
17.9.5.8. Leukemia and Lymphoma Society
17.9.5.9. Netherlands Cancer Institute
17.9.5.10. Alpine Immune Sciences
17.9.5.11. GE Global Research
17.9.5.12. Leiden University Medical Center
17.9.5.13. Genentech
17.9.5.14. Cell Designs Labs
17.9.5.15. University of California
17.9.5.16. BioLife Solutions
17.9.6. Future Outlook
17.10. Lion Biotechnologies
17.10.1. Company Overview
17.10.2. Financial Information
17.10.3. Product Portfolio
17.10.4. Manufacturing Capabilities
17.10.5. Collaborations
17.10.5.1. Lonza
17.10.5.2. H. Lee Moffitt Cancer Center and Research Institute
17.10.5.3. National Cancer Institute
17.10.5.4. National Institutes of Health
17.10.5.5. WuXiAppTec
17.10.5.6. MedImmune
17.10.5.7. PolyBioCept
17.10.5.8. Karolinska University Hospital
17.10.6. Upcoming Products: Next Generation TILs
17.10.7. Future Outlook
17.11. Novartis
17.11.1. Company Overview
17.11.2. Financial Information
17.11.3. Product Portfolio
17.11.4. Patent Litigation
17.11.5. Manufacturing Capabilities
17.11.6. Collaborations
17.11.6.1. University of Pennsylvania
17.11.6.2. Oxford BioMedica
17.11.6.3. Intellia Therapeutics and Caribou Biosciences
17.11.7. Future Outlook
17.12. Takara Bio
17.12.1. Company Overview
17.12.2. Financial Information
17.12.3. Product Portfolio
17.12.4. Manufacturing Capabilities
17.12.5. Collaborations
17.12.5.1. Tianjin Medical University, Cancer Institute and Hospital
17.12.5.2. Memorial Sloan Kettering Cancer Center
17.12.5.3. Jichi Medical University Hospital
17.12.5.4. Cellectis
17.12.5.5. Mile University School of Medicines
17.12.6. Future Outlook
17.13. Unum Therapeutics
17.13.1. Company Overview
17.13.2. Financial Information
17.13.3. Product Portfolio
17.13.4. Collaborations
17.13.4.1. Seattle Genetics
17.13.5. Future Outlook
18. Interview Transcripts
18.1. Chapter Overview
18.2. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
18.3. Peter Ho, Director, Process Development, Lion Biotechnologies
18.4. AinoKalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys
18.5. Adrian Bot, Vice President, Translational Sciences, Kite Pharma
18.6. Miguel Forte, Chief Operating Officer, TxCell
19. Conclusion
19.1. T-Cell Therapies Have Emerged as a Promising Segment of the Immunotherapy Market
19.2. Development Activity in the Domain is Led by Academic Institutes, Some of Which Have Collaborated with Industry Players
19.3. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
19.4. A Number of Novel Technological Platforms Have Emerged as Vital Enablers of Growth In This Market
19.5. A Significant Number of Strategic Alliances Have Been Forged in Order To Advance the Development of Different Product Candidates
19.6. Manufacturing Complexities and High Development Cost of These Therapies Necessitate Premium Pricing
19.7. Multiple Novel Types of Immunotherapies, Other Than CAR-T, TCR and TIL, are Expected to Emerge in The Mid-Long Run
19.8. Backed by a Progressive Pipeline and VC Support, the Market is Poised for Significant Growth
20. Appendix 1: Tabulated Data
21. Appendix 2: List of Companies and Organizations
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Difference between Active and Passive Immunotherapies
Figure 3.3 Difference between Specific and Non-Specific Immunotherapies
Figure 3.4 3Es of the Immune System
Figure 3.5 Strategies Employed for the Redirection of T-Cells
Figure 3.6 T-Cell Immunotherapy: Target Therapeutic Areas
Figure 3.7 T-Cell Immunotherapy: Key Challenges
Figure 4.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Figure 4.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Figure 4.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
Figure 4.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
Figure 4.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
Figure 4.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
Figure 4.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
Figure 4.8 T-Cell Immunotherapy Pipeline: Popular Target Indications
Figure 4.9 CAR-T Cell Immunotherapy: Popular Target Indications
Figure 4.10 TCR Cell Immunotherapy: Popular Target Indications
Figure 4.11 TIL Cell Immunotherapy: Popular Target Indications
Figure 4.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
Figure 4.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
Figure 4.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
Figure 4.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
Figure 4.16 TCR Therapy Pipeline: Distribution by Target Antigen
Figure 5.1 Historical Timeline: Development of CAR-T cells
Figure 5.2 CAR-T Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 5.3 CAR-T: Structure and Domains
Figure 5.4 CAR-T: CAR Generations Layout
Figure 5.5 Development of CAR-T Cells
Figure 5.6 Challenges Associated with CAR-T Therapy
Figure 5.7 CTL019: Industry Sponsored Clinical Trial Design
Figure 5.8 CTL019: Non-Industry Sponsored Clinical Trial Design
Figure 5.9 JCAR Series: Industry Sponsored Clinical Trial Design
Figure 5.10 JCAR Series: Non-Industry Sponsored Clinical Trial Design
Figure 5.11 KTE-C19: Clinical Trial Design
Figure 5.12 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 5.13 Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
Figure 5.14 Takara Bio’s CD19 CAR-T: Clinical Trial Design
Figure 6.1 TCR Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 6.2 TCR Cell Therapy: Development Process
Figure 6.3 NY-ESO TCR: Industry Sponsored Clinical Trial Design
Figure 6.4 MAGE A-10 TCR: Industry Sponsored Clinical Trial Design
Figure 6.5 ALT-801: Clinical Trial Design
Figure 6.6 IMCgp100: Clinical Trial Design
Figure 6.7 JTCR016: Clinical Trial Design
Figure 6.8 WT1 TCR: Clinical Trial Design
Figure 7.1 TIL Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 7.2 TIL Cell Therapy: Manufacturing Process
Figure 7.3 LN-144: Clinical Trial Design
Figure 7.4 Nantes University Hospital’s TIL Therapy: Clinical Trial Design
Figure 7.5 Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 7.6 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Design
Figure 8.1 Overall T-Cell Immunotherapy Market (Till 2030): Base Scenario (USD Billion)
Figure 8.2 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
Figure 8.3 Overall CAR-T Market Forecast(Till 2030): Base Scenario (USD Billion)
Figure 8.4 CTL019: Current Status by Highest Phase of Development
Figure 8.5 CTL019 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.6 KTE-C19: Current Status by Highest Phase of Development
Figure 8.7 KTE-C19 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.8 JCAR015 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.9 CBM-CD30 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.10 CBM-CD20 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.11 CBM-EGFR CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.12 Sinobioway Cell Therapy’s CD 19 CAR-T: Current Status by Highest Phase of Development
Figure 8.13 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.14 Takara Bio’s CD 19 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.15 GPC3 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.16 JCAR017 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.17 Overall TCR Market Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.18 IMCgp100 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.19 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.20 NY-ESO-1 TCR: Current Status by Highest Phase of Development
Figure 8.21 NY-ESO-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.22 HBV antigen specific TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.23 ALT-801: Current Status by Highest Phase of Development
Figure 8.24 ALT-801 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.25 JTCR016: Current Status by Highest Phase of Development
Figure 8.26 JTCR016 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.27 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.28 MAGE A3 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.29 WT-1 TCR: Current Status by Highest Phase of Development
Figure 8.30 WT-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.31 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.32 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
Figure 8.33 LN-144 Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.34 TIL Therapy (Nantes University) Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 8.35 TIL Therapy (Netherlands Cancer Institute) Sales Forecast(Till 2030): Base Scenario (USD Million)
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancer: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Bladder Cancer: Global Epidemiological Distribution
Figure 9.9 Kidney Cancer: Global Epidemiological Distribution
Figure 9.10 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2 Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Platforms
Figure 10.3 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 10.4 Properties of Enhanced T-Cell Platform
Figure 10.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1 T-Cell Immunotherapy Social Media Analysis: Twitter Trends, January 2011-June2016
Figure 11.2 T-Cell Immunotherapy Social Media Analysis: Highlights on Twitter, January 2011 - June 2016
Figure 11.3 T-Cell Immunotherapy Social Media Analysis: Twitter, Most Popular Candidates, January 2011-June 2016
Figure 12.1 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
Figure 12.2 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
Figure 12.3 T-Cell Immunotherapy: Leading Industry Collaborators
Figure 12.4 T-Cell Immunotherapy: Leading Non-industry Collaborators
Figure 12.5 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
Figure 12.6 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
Figure 13.1 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
Figure 13.2 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
Figure 13.3 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
Figure 13.4 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.1 Treg Cells: Functions
Figure 15.1 Cell Therapy Manufacturing: Key Steps
Figure 15.2 Cell Therapy Manufacturing: Scenarios
Figure 15.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
Figure 17.1 Adaptimmune: Funding Instances (USD Million)
Figure 17.2 Altor Bioscience: Funding Instances (USD Million)
Figure 17.3 bluebird bio: Funding Instances (USD Million)
Figure 17.4 Cellectis: Funding Instances (USD Million)
Figure 17.5 CBMG: Funding Instances (USD Million)
Figure 17.6 Immunocore: Funding Instances (USD Million)
Figure 17.7 Juno Therapeutics: Funding Instances (USD Million)
Figure 17.8 Kite Pharma: Funding Instances (USD Million)
Figure 17.9 Lion Biotechnologies: Funding Instances (USD Million)
Figure 17.10 Novartis: Revenues 2011-9M 2016 (USD Billion)
Figure 17.11 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
Figure 17.12 Takara Bio: Revenues, 2011-2016 (JPY Billion)
Figure 17.13 Unum Therapeutics: Funding Instances (USD Million)
Figure 17.14 ACTR Technology: Treatment Process
Figure 19.1 T-Cell Immunotherapy Market Landscape: Industry Participants
Figure 19.2 T-Cell Immunotherapy Market Landscape: Non-industry Participants
Figure19.3 T-Cell Immunotherapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 3.2 Retroviral Vectors: Salient Features
Table 3.3 Lentiviral Vectors: Salient Features
Table 4.1 CAR-T Cell Immunotherapy: Clinical Pipeline
Table 4.2 CAR-T Cell Immunotherapy: Preclinical / Discovery Pipeline
Table 4.3 TCR Cell Therapy: Clinical Pipeline
Table 4.4 TCR Cell Immunotherapy: Preclinical / Discovery Pipeline
Table 4.5 TIL Cell Immunotherapy: Clinical Pipeline
Table 4.6 TIL Cell Immunotherapy: Preclinical / Discovery Pipeline
Table 5.1 Key Characteristics of CAR-T cells
Table 5.2 Comparison Between 1st and 2nd Generation CARs
Table 5.3 Grading Criteria for CRS
Table 5.4 Safety Switches under Development for CART-T Therapy
Table 5.5 CD19 CAR-T Cells: Preclinical Results
Table 5.6 Other Targets under Clinical/Preclinical Studies for CAR-T Therapy
Table 5.7 CTL019: Clinical Studies
Table 5.8 CTL019: Clinical Trial Endpoints (ALL)
Table 5.9 CTL019: Clinical Trial Endpoints (CLL/MM/NHL)
Table 5.10 JCAR Series: Molecules in Clinical Development
Table 5.11 JCAR: CAR-T Design
Table 5.12 JCAR014: Current Status of Development
Table 5.13 JCAR015: Current Status of Development
Table 5.14 JCAR017: Current Status of Development
Table 5.15 JCAR018: Current Status of Development
Table 5.16 JCAR020: Current Status of Development
Table 5.17 JCAR023: Current Status of Development
Table 5.18 JCAR024: Current Status of Development
Table 5.19 JCAR Series: Clinical Trial Endpoints (Phase II)
Table 5.20 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 5.21 JCAR: Dosage Regimen
Table 5.22 KTE-C19: Clinical Studies
Table 5.23 KTE-C19: Clinical Trial Endpoints
Table 5.24 KTE-C19: ZUMA-1 Phase II Results (≥3 months Follow-Up)
Table 5.25 KTE-C19: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
Table 5.26 CBM CAR-T Series: Clinical Products,
Table 5.27 CBM-CD19.1 CAR-T: Clinical Studies
Table 5.28 CBM-CD20 CAR-T: Clinical Status
Table 5.29 CBM-CD30.1 CAR-T: Clinical Status
Table 5.30 CBM-EGFR.1 CAR-T: Clinical Status
Table 5.31 Cellular Biomedicine’s CAR-T Series: Clinical Trial Endpoints
Table 5.32 CBM CAR-T Series: Patent Portfolio
Table 5.33 Takara Bio’s CD19 CAR-T: Current Status of Development
Table 5.34 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 6.1 CAR-T Cell and TCR Based Therapies: Key Differences
Table 6.2 NY-ESO TCR: Clinical Studies
Table 6.3 MAGE-A10: Clinical Studies
Table 6.4 NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
Table 6.5 ALT-801: Clinical Studies
Table 6.6 ALT-801: Clinical Trial Endpoints
Table 6.7 IMCgp100: Clinical Studies
Table 6.8 IMCgp100: Clinical Trial Endpoints
Table 6.9 JTCR016: Clinical Studies
Table 6.10 JTCR016: Clinical Trial Endpoints
Table 6.11 WT1 TCR: Clinical Studies
Table 6.12 WT1 TCR: Clinical Trial Endpoints
Table 7.1 LN-144: Clinical Trial Endpoints
Table 7.2 LN-144: Patent Portfolio
Table 7.3 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 7.4 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 8.1 T-Cell Immunotherapy: List of Forecasted Molecules
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Comparison of Marketed Targeted Therapeutics: Leukemia
Table 9.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
Table 9.4 T-Cell Immunotherapy: Targets under Investigation for Leukaemia
Table 9.5 T-Cell Immunotherapy: Targets under Investigation for Lymphoma
Table 9.6 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
Table 9.7 T-Cell Immunotherapy: Targets under Investigation for Multiple Myeloma
Table 9.8 Comparison of Marketed Targeted Therapeutics: Melanoma
Table 9.9 TIL Therapy: Historical Development of Treatment Protocols at the National Cancer Institute
Table 9.10 Comparison of Marketed Therapeutics: Lung Cancer
Table 9.11 T-Cell Immunotherapy: Targets under Investigation for Lung Cancer
Table 9.12 Comparison of Marketed Targeted Therapeutics: Renal Cell Carcinoma
Table 9.13 T-Cell Immunotherapy: Targets under Investigation for Ovarian Cancer
Table 9.14 Comparison of Marketed Therapeutics: Breast Cancer
Table 9.15 T-Cell Immunotherapy: Targets under Investigation for Breast Cancer
Table 10.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
Table 10.2 Editas Medicine: Funding Instances
Table 10.3 Editas Medicine: Collaborations
Table 10.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
Table 10.5 Intellia Therapeutics: Funding Instances
Table 10.6 Intellia Therapeutics: Collaborations
Table 10.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
Table 10.8 CRISPR Therapeutics: Funding Instances
Table 10.9 CRISPR Therapeutics: Collaborations
Table 10.10 Cellectis: Funding Instances
Table 10.11 Cellectis: Collaborations
Table 10.12 bluebird bio: Funding Instances
Table 10.13 bluebird bio: Collaborations
Table 10.14 Sangamo Biosciences: Funding Instances
Table 10.15 Sangamo Biosciences: Collaborations
Table 10.16 Unum Therapeutics: Funding Instances
Table 10.17 Unum Therapeutics: Collaborations
Table 10.18 Celyad: Funding Instances
Table 10.19 Celyad: Collaborations
Table 10.20 Intrexon: Funding Instances
Table 10.21 Intrexon: Collaborations
Table 10.22 Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.23 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.24 Bellicum Pharmaceuticals: Funding Instances
Table 10.25 Bellicum Pharmaceuticals: Collaborations
Table 10.26 Theravectys: Funding Instances
Table 10.27 Formula Pharmaceuticals: Collaborations
Table 12.1 T-Cell Immunotherapy: Recent Collaborations
Table13.1 T-Cell Immunotherapy: List of Funding Rounds / Grants and Investors Involved
Table 14.1 List of Other Novel T-Cell Immunotherapies
Table 14.2 Treg Cell: Properties
Table 15.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 15.2 Cell Therapy Manufacturing: Contract Manufacturers
Table 16.1 Marketed Cell / Gene Therapies: Price
Table 16.2 Marketed Targeted Drugs for Cancer: Price
Table 16.3 T-Cell Immunotherapy: Expert Opinions on Pricing
Table 17.1 Adaptimmune: T-Cell Immunotherapy Pipeline
Table 17.2 Adaptimmune: T-Cell Immunotherapy Collaborations
Table 17.3 AltorBioScience: T-Cell Immunotherapy Pipeline
Table 17.4 AltorBioScience: T-Cell Immunotherapy Collaborations
Table 17.5 bluebird bio: T-Cell Immunotherapy Pipeline
Table 17.6 bluebird bio: T-Cell Immunotherapy Collaborations
Table 17.7 Cellectis: T-Cell Immunotherapy Pipeline
Table 17.8 Cellectis: T-Cell Immunotherapy Collaborations
Table 17.9 Cellular Biomedicine Group: T-Cell Immunotherapy Pipeline
Table 17.10 Cellular Biomedicine Group: T-Cell Immunotherapy Collaborations
Table 17.11 Immunocore: T-Cell Immunotherapy Pipeline
Table 17.12 Immunocore: T-Cell Immunotherapy Collaborations
Table 17.13 Juno Therapeutics: T-Cell Immunotherapy Pipeline
Table 17.14 Juno Therapeutics: T-Cell Immunotherapy Collaborations
Table 17.15 Kite Pharma: T-Cell Immunotherapy Pipeline
Table 17.16 Kite Pharma: T-Cell Immunotherapy Collaborations
Table 17.17 Lion Biotechnologies: T-Cell Immunotherapy Pipeline
Table 17.18 Lion Biotechnologies: T-Cell Immunotherapy Collaborations
Table 17.19 Novartis: T-Cell Immunotherapy Pipeline
Table 17.20 Novartis: T-Cell Immunotherapy Collaborations
Table 17.21 Takara Bio: T-Cell Immunotherapy Pipeline
Table 17.22 Takara Bio: T-Cell Immunotherapy Collaborations
Table 17.23 Unum Therapeutics: T-Cell Immunotherapy Pipeline
Table 17.24 Unum Therapeutics: T-Cell Immunotherapy Collaborations
Table 20.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Table 20.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Table 20.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
Table 20.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
Table 20.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
Table 20.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
Table 20.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
Table 20.8 T-Cell Immunotherapy: Popular Target Indications
Table 20.9 CAR-T Cell Immunotherapy: Popular Target Indications
Table 20.10 TCR Cell Immunotherapy: Popular Target Indications
Table 20.11 TIL Cell Immunotherapy: Popular Target Indications
Table 20.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
Table 20.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
Table 20.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
Table 20.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
Table 20.16 TCR Therapy Pipeline: Distribution by Target Antigen
Table 20.17 Overall T-Cell Immunotherapy Market (Till 2030): Conservative Scenario (USD Billion)
Table 20.18 Overall T-Cell Immunotherapy Market(Till 2030): Base Scenario (USD Billion)
Table 20.19 Overall T-Cell Immunotherapy Market(Till 2030): Optimistic Scenario (USD Billion)
Table 20.20 T-Cell Therapy Market, 2020, 2025 and 2030: Conservative Scenario (USD Million)
Table 20.21 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
Table 20.22 T-Cell Therapy Market, 2020, 2025 and 2030: Optimistic Scenario (USD Million)
Table 20.23 Overall CAR-T Market Forecast(Till 2030): Conservative Scenario (USD Billion)
Table 20.24 Overall CAR-T Market Forecast (Till 2030): Base Scenario (USD Billion)
Table 20.25 Overall CAR-T Market Forecast (Till 2030): Optimistic Scenario (USD Billion)
Table 20.26 CTL019 Sales Forecast(Till 2030): Conservative Scenario (USD Million
Table 20.27 CTL019 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.28 CTL019 Sales Forecast(Till 2030): Optimistic Scenario (USD Million
Table 20.29 KTE-C19 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.30 KTE-C19 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.31 KTE-C19 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.32 JCAR015 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.33 JCAR015 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.34 JCAR015 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.35 CBM-CD30 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.36 CBM-CD30 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.37 CBM-CD30 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.38 CBM-CD20 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.39 CBM-CD20 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.40 CBM-CD20 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.41 CBM-EGFR CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.42 CBM-EGFR CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.43 CBM-EGFR CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.44 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.45 Sinobioway Cell Therapy’s CD 19CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.46 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.47 Takara Bio’s CD 19 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.48 Takara Bio’s CD 19CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.49 Takara Bio’s CD 19 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.50 GPC3 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.51 GPC3 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.52 GPC3 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.53 JCAR017 Sales Forecast, (Till 2030): Conservative Scenario (USD Million)
Table 20.54 JCAR017 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.55 JCAR017 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.56 Overall TCR Market Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.57 Overall TCR Market Forecast(Till 2030): Base Scenario (USD Million)
Table 20.58 Overall TCR Market Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.59 IMCgp100 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.60 IMCgp100 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.61 IMCgp100 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.62 HPV-16E6-TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.63 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.64 HPV-16E6-TCR Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.65 NY-ESO-1 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.66 NY-ESO-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.67 NY-ESO-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.68 HBV antigen specific TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.69 HBV antigen specific TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.70 HBV antigen specific TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.71 ALT-801 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.72 ALT-801 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.73 ALT-801 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.74 JTCR016 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.75 JTCR016 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.76 JTCR016 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.77 KITE-718 (MAGE A3/A6) Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.78 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.79 KITE-718 (MAGE A3/A6) Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.80 MAGE A3 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.81 MAGE A3 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.82 MAGE A3 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.83 WT-1 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.84 WT-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.85 WT-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.86 MAGE A-10 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.87 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.88 MAGE A-10 TCR Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.89 Overall TIL Market Forecast(Till 2030): Conservative Scenario (USD Billion)
Table 20.90 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
Table 20.91 Overall TIL Market Forecast(Till 2030): Optimistic Scenario (USD Billion)
Table 20.92 LN-144 Sales Market Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.93 LN-144 Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.94 LN-144 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
Table 20.95 Nantes University Hospital’s TIL Therapy Sales Forecast(Till 2030): Conservative Scenario (USD Million)
Table 20.96 Nantes University Hospital’s TIL Therapy Sales Forecast(Till 2030): Base Scenario (USD Million)
Table 20.97 Nantes University Hospital’s TIL Therapy Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.98 Netherland Cancer Institute’s TIL Therapy Sales Market Forecast, 2018-2030: Conservative Scenario (USD Million)
Table 20.99 Netherland Cancer Institute’s TIL Therapy Sales Forecast, 2018-2030: Base Scenario (USD Million)
Table 20.100 Netherland Cancer Institute’s TIL Therapy Sales Forecast, 2018-2030: Optimistic Scenario (USD Million)
Table 20.101 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
Table 20.102 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
Table 20.103 T-cell Immunotherapy: Leading Industry Collaborators
Table 20.104 T-cell immunotherapy: Leading Non-industry Collaborators
Table 20.105 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
Table 20.106 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
Table 20.107 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
Table 20.108 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
Table 20.109 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
Table 20.110 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
Table 20.111 Adaptimmune: Funding Instances (USD Million)
Table 20.112 AltorBioScience: Funding Instances (USD Million)
Table 20.113 blubird bio: Funding Instances (USD Million)
Table 20.114 Cellectis: Funding Instances (USD Million)
Table 20.115 Cellular Biomedicine Group: Funding Instances (USD Million)
Table 20.116 Immunocore: Funding Instances (USD Million)
Table 20.117 Juno Therapeutics: Funding Instances (USD Million)
Table 20.118 Kite Pharma: Funding Instances (USD Million)
Table 20.119 Lion Biotechnologies: Funding Instances (USD Million)
Table 20.120 Novartis: Revenues 2011-9M 2016 (USD Billion)
Table 20.121 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
Table 20.122 Takara Bio: Revenues, 2011-2016 (JPY Million)
Table 20.123 Unum Therapeutics: Funding Instances (USD Million)
Table 20.124 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES